Evidence map›Paper›PMID 27730274›Full record

ReviewDer Nervenarzt2016

[Progressive multifocal leukoencephalopathy].

C Warnke, M P Wattjes, O Adams, H-P Hartung, R Martin, T Weber, M Stangel

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. The Cerebrospinal Fluid in Multiple Sclerosis.Frontiers in immunology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

C WarnkeKlinik für Neurologie, Medizinische Fakultät, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland. warnke@uni-duesseldorf.de.
M P WattjesAbteilung für Radiologie und Nuklearmedizin, VU University Medical Center, Amsterdam, Niederlande.
O AdamsInstitut für Virologie, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.
H-P HartungKlinik für Neurologie, Medizinische Fakultät, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland.
R MartinKlinik für Neurologie, Universitätsspital Zürich, Zürich, Schweiz.
T WeberKlinik für Neurologie, Kath. Marienkrankenhaus, Hamburg, Deutschland.
M StangelKlinik für Neurologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
Heinrich Heine University Düsseldorf · DEMarienkrankenhaus Hamburg · DEMedizinische Hochschule Hannover · DEUniversity Hospital of Zurich · CHUniversity Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive multifocal leukoencephalopathy (PML) is a disease of immunosuppressed patients caused by the JC polyomavirus (JCPyV). Due to the elevated risk in patients treated with natalizumab for multiple sclerosis (MS) and also treatment with other biologicals for different indications, the relevance of PML has increased in recent years. This article summarizes the published knowledge on the biology and pathogenesis of PML with a focus on the role of cerebrospinal fluid diagnostics in the work-up for PML and the current PML case definition. Current recommendations regarding risk management are discussed, as are possible therapies and prevention.

Indexed as

Diagnostic Techniques, NeurologicalBiomarkersCase ManagementEvidence-Based MedicineHumansLeukoencephalopathy, Progressive MultifocalTreatment OutcomeBiomarkersCerebrospinal fluidJC polyomavirusMultiple sclerosisNatalizumabPML

Identifiers

PMID27730274
OpenAlexW1493570251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.